Youlia Kirova

9.3k total citations
325 papers, 5.0k citations indexed

About

Youlia Kirova is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Youlia Kirova has authored 325 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 166 papers in Cancer Research, 141 papers in Oncology and 108 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Youlia Kirova's work include Breast Cancer Treatment Studies (161 papers), Advanced Radiotherapy Techniques (77 papers) and Breast Lesions and Carcinomas (67 papers). Youlia Kirova is often cited by papers focused on Breast Cancer Treatment Studies (161 papers), Advanced Radiotherapy Techniques (77 papers) and Breast Lesions and Carcinomas (67 papers). Youlia Kirova collaborates with scholars based in France, China and Italy. Youlia Kirova's co-authors include Alain Fourquet, R. Dendale, Bernard Asselain, François Campana, Pierre Loap, Marc A. Bollet, Brigitte Sigal‐Zafrani, Alexia Savignoni, Jacques R. Vilcoq and N. Fournier‐Bidoz and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Youlia Kirova

298 papers receiving 4.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Youlia Kirova France 37 2.2k 2.1k 1.5k 1.2k 1.0k 325 5.0k
Pauline T. Truong Canada 41 3.1k 1.4× 2.0k 1.0× 1.1k 0.8× 1.6k 1.3× 1.1k 1.1× 174 5.3k
Jürgen Dunst Germany 45 1.6k 0.8× 1.8k 0.8× 3.0k 2.0× 986 0.8× 863 0.8× 234 6.9k
Thomas A. DiPetrillo United States 41 1.7k 0.8× 1.3k 0.6× 2.5k 1.7× 936 0.8× 1.3k 1.3× 151 5.3k
Claudia Sangalli Italy 33 1.6k 0.7× 1.4k 0.7× 1.3k 0.9× 1.1k 0.9× 539 0.5× 101 3.4k
Remi A. Nout Netherlands 49 1.3k 0.6× 2.3k 1.1× 1.6k 1.1× 1.3k 1.1× 497 0.5× 206 10.2k
John M. Kurtz Switzerland 35 2.1k 1.0× 1.5k 0.7× 1.1k 0.7× 1.4k 1.2× 448 0.4× 68 4.2k
Claus Kamby Denmark 30 1.7k 0.8× 1.6k 0.8× 806 0.6× 796 0.7× 280 0.3× 93 3.6k
Julia White United States 40 4.7k 2.2× 2.2k 1.1× 1.2k 0.8× 2.2k 1.8× 2.3k 2.2× 185 6.6k
Csaba Polgár Hungary 30 3.0k 1.4× 1.0k 0.5× 711 0.5× 1.6k 1.4× 1.7k 1.7× 210 4.2k
Mahmut Özsahin Switzerland 43 854 0.4× 2.3k 1.1× 2.1k 1.4× 929 0.8× 505 0.5× 149 6.9k

Countries citing papers authored by Youlia Kirova

Since Specialization
Citations

This map shows the geographic impact of Youlia Kirova's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Youlia Kirova with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Youlia Kirova more than expected).

Fields of papers citing papers by Youlia Kirova

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Youlia Kirova. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Youlia Kirova. The network helps show where Youlia Kirova may publish in the future.

Co-authorship network of co-authors of Youlia Kirova

This figure shows the co-authorship network connecting the top 25 collaborators of Youlia Kirova. A scholar is included among the top collaborators of Youlia Kirova based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Youlia Kirova. Youlia Kirova is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Loap, Pierre, Youlia Kirova, & R. Dendale. (2024). Primary ophthalmic natural killer/T-cell lymphoma: A population-based study. Bulletin du Cancer. 111(3). 310–313.
2.
Renard, Sophie, et al.. (2024). Electron radiation therapy: Back to the future?. Cancer/Radiothérapie. 28(6-7). 553–559. 1 indexed citations
3.
Hannoun‐Lévi, Jean‐Michel, Alexia Savignoni, Caroline Malhaire, et al.. (2024). Management of second ipsilateral breast tumor event: An advocacy for a randomized trial. Cancer/Radiothérapie. 28(2). 188–194. 3 indexed citations
4.
Loap, Pierre, et al.. (2024). Determinants of radiation dose to immune cells during breast radiotherapy. Strahlentherapie und Onkologie. 201(2). 106–114. 3 indexed citations
5.
Loap, Pierre, et al.. (2024). Concurrent Use of Radiotherapy and Ribociclib. American Journal of Clinical Oncology. 47(12). 574–579. 2 indexed citations
6.
Choi, J. Isabelle, Alicia Lozano, Alexandra L. Hanlon, et al.. (2024). PTCOG international survey of practice patterns and trends in utilization of proton therapy for breast cancer. Clinical and Translational Radiation Oncology. 48. 100847–100847. 2 indexed citations
7.
8.
Barcellini, Amelia, Pierre Loap, Kazutoshi Murata, et al.. (2021). PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?. Cancers. 13(21). 5380–5380. 32 indexed citations
9.
Kirova, Youlia, et al.. (2021). In vitro effects of Trastuzumab Emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells. Cancer/Radiothérapie. 25(2). 126–134. 11 indexed citations
10.
Beddok, Arnaud, et al.. (2021). Is cancer a prognostic factor for severe COVID-19, especially for breast cancer patients?. Cancer/Radiothérapie. 26(3). 491–493. 3 indexed citations
11.
Loap, Pierre & Youlia Kirova. (2020). Fast Neutron Therapy for Breast Cancer Treatment: An Effective Technique Sinking into Oblivion. International Journal of Particle Therapy. 7(3). 61–64. 4 indexed citations
12.
Ngo, Carine, Marick Laé, Martial Caly, et al.. (2017). Contrôle de qualité interne de la détermination du statut HER2 dans les cancers du sein : expérience d’un centre de lutte contre le cancer. Bulletin du Cancer. 104(7-8). 608–617. 2 indexed citations
13.
14.
Laé, Marick, et al.. (2015). Can c-myc amplification reliably discriminate postradiation from primary angiosarcoma of the breast?. Cancer/Radiothérapie. 19(3). 168–174. 38 indexed citations
15.
Cao, Lu, Weigang Hu, Youlia Kirova, et al.. (2014). Potential impact of cardiac dose–volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy. Cancer/Radiothérapie. 18(2). 119–124. 22 indexed citations
16.
Thariat, Juliette, Youlia Kirova, G. Milano, & F. Mornex. (2014). Association d’une chimiothérapie ou d’un traitement ciblé à une irradiation stéréotaxique : état des lieux et recommandations préliminaires. Cancer/Radiothérapie. 18(4). 270–279. 15 indexed citations
17.
Laé, Marick, Anna Almeida, Pierre de la Grange, et al.. (2012). A transcriptome signature of endothelial lymphatic cells coexists with the chronic oxidative stress signature in radiation-induced post-radiotherapy breast angiosarcomas. Carcinogenesis. 33(7). 1399–1405. 16 indexed citations
18.
Scodan, Romuald Le, Christophe Massard, Maya Gutierrez, et al.. (2011). Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 11(1). 395–395. 48 indexed citations
19.
Chargari, Cyrus, Jean‐Yves Pierga, Marc A. Bollet, et al.. (2010). Preliminary Results of Whole Brain Radiotherapy With Concurrent Trastuzumab for Treatment of Brain Metastases in Breast Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 81(3). 631–636. 49 indexed citations
20.
Chargari, Cyrus, Youlia Kirova, Véronique Dièras, et al.. (2009). Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients. Journal of Neuro-Oncology. 93(3). 379–384. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pauline T. Truong Breakdown of academic impact, for papers by Jürgen Dunst Breakdown of academic impact, for papers by Thomas A. DiPetrillo Breakdown of academic impact, for papers by Claudia Sangalli Breakdown of academic impact, for papers by Remi A. Nout Breakdown of academic impact, for papers by John M. Kurtz Breakdown of academic impact, for papers by Claus Kamby Breakdown of academic impact, for papers by Julia White Breakdown of academic impact, for papers by Csaba Polgár Breakdown of academic impact, for papers by Mahmut Özsahin
Rankless by CCL
2026